Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2018-07-02 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about patent allowances and upcoming Phase III results, but does not contain detailed financial statements or substantive financial data. The document length is short (1974 characters) and it primarily serves as a regulatory announcement of new developments rather than a full report. According to the rules, Form 6-K filings are typically regulatory filings for foreign issuers to disclose material information. Therefore, this document fits best under Regulatory Filings (RNS).
2018-07-02 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a co-promotion agreement for a drug. The document is short (1988 characters) and primarily serves as a regulatory announcement of a business update rather than a full financial report or detailed filing. It does not contain financial statements, audit information, or detailed management discussion. Form 6-K filings are typically used for current reports by foreign private issuers and often fall under Regulatory Filings (RNS) in classification schemes. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-06-28 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. Form 6-K is used for submitting current reports by foreign private issuers and typically includes press releases or other material information. The text mentions a press release about positive Phase II results for a drug, which is incorporated by reference. The document length is short (1969 characters), and it primarily serves as a regulatory filing to report material information rather than a full financial report or earnings release. There is no detailed financial data or comprehensive report content. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-05-30 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to SEC rules. It includes a press release about a new U.S. patent for an experimental therapy. The document is short (1940 characters) and primarily serves as a regulatory update rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis. Form 6-K filings are typically periodic reports for foreign issuers and often classified under Regulatory Filings (RNS) when they do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-05-29 English
FORM S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans. It includes detailed information about the securities to be registered, the plan under which they will be issued, and legal provisions related to indemnification and insurance of directors and officers. It is not an annual report, earnings release, or any other financial report but a registration statement related to share issuance under an employee plan. This fits the category of Share Issue/Capital Change announcements, as it relates to registering shares for issuance under a stock award plan.
2018-05-23 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about an upcoming investor webcast. The document is short (1945 characters) and primarily serves as a regulatory filing to report current events or updates rather than a full financial report or detailed presentation. It does not contain financial statements, detailed management discussion, or audit information. It also does not announce voting results, capital changes, or legal proceedings. Given the nature of Form 6-K filings, which are periodic reports of material events for foreign issuers, and the content being a press release about an investor webcast, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-05-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.